Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463582 | 1.00 | KCNH2 (0.46) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4475110 | 0.99 | KCNH2 (0.45) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4475114 | 0.99 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL4467618 | 0.88 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL4467615 | 0.88 | KCNH2 (0.43) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4474584 | 0.87 | KCNH2 (0.42) | KCNH2 | |
| Hydrochloric Acid SCHEMBL4474589 | 0.87 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL2955652 | 0.82 | KCNH2 (0.46) | KCNH2 | |
| SCHEMBL2954817 | 0.80 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL13382608 | 0.80 | KCNH2 (0.59) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592334-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | claimed |
| US-20080139540-A1 | 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | claimed |
| US-7592334-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7592334-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7592334-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20080139540-A1 | 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139540-A1 | 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139540-A1 | 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139540-A1 | 6-[({3-hydroxy-8-[6-(methyloxy)-1,5-naphthyridin-4-yl]-8-azaspiro[4.5]dec-2-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]thiazin-3-on; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NT5C3B, NT5C, SPOUT1 | KCNH2 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.